Table 2

 Observed (OBS), expected (EXP) number of malignancies grouped as smoking related (upper gastrointestinal tract + airway + urinary tract), blood malignancies (leukaemias + myelomas), lymphomas, and other carcinomas and sarcomas (breast + genital + other gastrointestinal + abdominal cavity + skin + musculoskeletal) for the anti-TNF treated and comparison cohort, respectively

*One laryngeal carcinoma, diagnosed >3 years after anti-TNF withdrawal, not reported to the SSATG registry; †one prostate carcinoma and one cutaneous carcinoma, diagnosed >1 year after anti-TNF withdrawal, not reported to the SSATG registry; ‡one cervical uterine carcinoma in a patient with a previous carcinoma thus excluded from the registry search, and three basal cell carcinomas. Basal cell carcinomas are not registered in the cancer registry, but it includes all other cutaneous cancers—both melanomas and non-melanoma cancers; §moved abroad and thus excluded from the tumour registry search.
Standardised incidence ratios (SIRs) and 95 per cent confidence interval (95% CI) are also shown. For the anti-TNF treated patients the numbers of malignancies reported to the SSATG register (OBS SSATG) are also shown.
Comparison cohort (n = 800); person years  =  3948; follow up age 0–99, male+female
Smoking related218.52.51.5 to 3.8
Other cancers44381.20.8 to 1.6
Blood malignancies, including myeloma21.81.10.1 to 4.0
Lymphomas21.61.30.2 to 4.5
All malignancies6949.91.41.1 to 1.8
Anti-TNF cohort (n = 757); person years  = 1603; follow up age 0–99, male+female
Smoking related5* to 5.14
Other cancers6† to 1.28‡
Blood malignancies including myeloma00.400 to 9.2
Lymphomas50.411.53.7 to 26.95
All malignancies1613.41.10.6 to 1.818